Related Experiment Video
Updated: May 31, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.
Axel Bex1, Michael Jewett2, Bryan Lewis3
1Division of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, Royal Free London NHS Foundation Trust, University College London, London, UK.
Neoadjuvant systemic treatments improve outcomes for many cancers but not yet for renal cell carcinoma (RCC). International collaboration is crucial for developing adaptive perioperative immunotherapy strategies for high-risk RCC patients.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma Research
Background:
- Neoadjuvant systemic treatments have shown significant success in improving outcomes for various solid tumors.
- However, this therapeutic advancement has not yet translated to comparable benefits in renal cell carcinoma (RCC).
Discussion:
- The efficacy of current neoadjuvant strategies in RCC remains limited, highlighting a critical unmet need.
- There is a pressing requirement for a unified approach and global cooperation to advance treatment protocols.
Key Insights:
- Adaptive perioperative immunotherapy presents a promising avenue for enhancing treatment efficacy in RCC.
- Focusing on patients with a high risk of recurrence is essential for maximizing the impact of novel strategies.
Outlook:
- Establishing an international consensus is vital for the coordinated development and implementation of advanced perioperative immunotherapy for RCC.
- Future research should prioritize adaptive strategies that can be tailored to individual patient responses and disease characteristics.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Cancer Survival Analysis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer
Tumor Immunotherapy